J.W. Cole Advisors Inc. Purchases 5,198 Shares of Thermo Fisher Scientific Inc. $TMO

J.W. Cole Advisors Inc. increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 135.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,026 shares of the medical research company’s stock after acquiring an additional 5,198 shares during the period. J.W. Cole Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $3,660,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. North Star Asset Management Inc. raised its stake in shares of Thermo Fisher Scientific by 6.7% during the 2nd quarter. North Star Asset Management Inc. now owns 60,563 shares of the medical research company’s stock worth $24,556,000 after purchasing an additional 3,824 shares during the period. Manchester Capital Management LLC raised its position in Thermo Fisher Scientific by 1.8% in the second quarter. Manchester Capital Management LLC now owns 2,308 shares of the medical research company’s stock worth $936,000 after acquiring an additional 41 shares during the period. FourThought Financial Partners LLC boosted its stake in Thermo Fisher Scientific by 3.8% in the second quarter. FourThought Financial Partners LLC now owns 10,154 shares of the medical research company’s stock valued at $4,117,000 after acquiring an additional 371 shares during the last quarter. SlateStone Wealth LLC grew its position in shares of Thermo Fisher Scientific by 6.9% during the 2nd quarter. SlateStone Wealth LLC now owns 7,505 shares of the medical research company’s stock valued at $3,043,000 after acquiring an additional 484 shares during the period. Finally, Cornerstone Capital Inc. raised its holdings in shares of Thermo Fisher Scientific by 6.0% in the 2nd quarter. Cornerstone Capital Inc. now owns 50,205 shares of the medical research company’s stock worth $20,356,000 after purchasing an additional 2,840 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on TMO. Wells Fargo & Company increased their price objective on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Barclays increased their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating on the stock. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Nineteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 7,250 shares of the company’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $64,400,668.20. This represents a 5.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the transaction, the executive vice president directly owned 21,152 shares in the company, valued at $12,144,420.80. This trade represents a 1.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 52,570 shares of company stock valued at $30,382,352 over the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO opened at $593.41 on Thursday. The stock has a market capitalization of $222.95 billion, a P/E ratio of 34.28, a PEG ratio of 3.27 and a beta of 0.82. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The stock has a 50-day moving average price of $544.05 and a 200-day moving average price of $477.35.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the previous year, the company posted $5.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific announced that its board has authorized a share repurchase plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.